Novo Nordisk, the pharmaceutical company behind the popular medications Ozempic and Wegovy, has initiated legal action to prevent compounding pharmacies from creating and distributing less expensive alternatives to its products.
The company contends that the intricate nature of these drugs makes them difficult to replicate safely, urging the FDA to prohibit compounded versions over concerns about potential health risks.
Semaglutide, the active ingredient in both Ozempic and Wegovy, has faced a significant supply shortage for more than two years, leading compounding pharmacies to step in and provide lower-cost alternatives. However, Novo Nordisk asserts that these compounded versions pose safety risks since they lack FDA approval.
The lawsuit underscores the ongoing debate surrounding drug pricing and access to essential medications as patients seek more affordable options amid rising healthcare costs.